Yatharth Hospital & Trauma Care Services Limited share price

Key numbers

Market cap

₹ 10,805 Cr

Current price

₹ 1,121.40

52-week high / low

₹ 1,184 / 538

Stock P/E

59.9

Book value

₹ 184.7

Dividend yield

0.09%

ROCE

12.6%

ROE

10.4%

Debt to equity

0.15

Sales growth (3 yrs)

32.0%

Profit growth (3 yrs)

38.7%

1-year return

42.9%

About Yatharth Hospital & Trauma Care Services Limited

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Quarterly results

Consolidated figures in ₹ crores

Concall summary (2026-08-18)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

• The Gurugram construction is progressing as per expectations and we expect the hospital to go live by quarter 1 of the next fiscal with a potential to achieve an ARPOB of INR50,000 plus.
• If you see what the guidance we are giving for the EBITDA, we are touching from 24 to 25% EBITDA margin as per the guidance.

Growth & demand

• More encouragingly, we achieved a record revenue growth of 51% year- on-year and an EBITDA growth of 39% year-on-year.
• In recognition to the above performance, the Board today approved a maiden interim dividend of 5% of face value for all our shareholders, ensuring that shareholders benefit from the growth and investments being done by the group.

Margins & costs

• Over the past couple of quarters, our profitability has also improved meaningfully with operating leverage kicking in as reflected in our adjusted EBITDA margin, excluding the impact of New Delhi and Faridabad sector 20 stood at 28.1% this quarter.
• EBITDA for the quarter was highest ever at INR917 million with PAT stood at INR454 million, while the consolidated EBITDA stood at 23.3%, the adjusted EBITDA margin, excluding the impact of New Delhi and Faridabad Sector 20 stood at 28.1%.

Capex & expansion

• Our newer hospitals at Greater Faridabad, New Delhi Faridabad Sector 20 and Agra collectively contributed 27% to the mix this quarter, especially our acquisition playbook has delivered signs of early success.
• With the upcoming Gurugram facility and brownfield expansion plan at Noida Extension and Greater Noida, our total bed capacity will reach over 3,200 beds.

Balance sheet & cash

• Expanding our global outreach, we opened the Yatharth Information Center in Uzbekistan and have also leveraged our partnerships with health care institutions as well as und ertook many OPD initiatives across key market s like Asia, Africa and Middle East.
• If you see that we have a debt in our books in March of nearly around INR210 crores which is now being increased to around INR300 crores.

Peers in Medical Care Facilities

• Apollo Hospitals Enterprise Limited
• Max Healthcare Institute Limited
• Manipal Health Enterprises Limited
• Aster DM Quality Care Limited
• Fortis Healthcare Limited
• Global Health Limited
• Narayana Hrudayalaya Limited
• Krishna Institute of Medical Sciences Limited
• Rainbow Children's Medicare Limited
• Park Medi World Limited